secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001193125-26-130283
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027
--------------------------------------------------------------------------------

- Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.
- Proceeds to fund development of PI3Kα pan-mutant inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies).
- IND submissions for OKI-345 and OKI-355 planned for H1 2027; no further independent development of OKI-219.
- Dr. Liam Ratcliffe appointed to board effective at closing, designated by lead investor AI Biotechnology.
- Officers/directors and company subject to 180-day lock-up (or until registration effective) on share issuance/sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/0001193125-26-130283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526130283/d910791d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-130283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer